Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AstraZeneca | 9.56% | $293.32M | $300.81B | 24.33% | 80 Outperform | |
| HSBC Holdings | 9.23% | $283.14M | £218.61B | 50.15% | 80 Outperform | |
| Shell (UK) | 7.62% | $233.82M | £182.70B | 26.30% | 73 Outperform | |
| Rolls-Royce Holdings | 4.65% | $142.74M | £109.48B | 71.27% | 71 Outperform | |
| Unilever | 4.51% | $138.29M | £105.90B | ― | 72 Outperform | |
| British American Tobacco | 4.07% | $124.78M | £94.69B | 37.57% | 71 Outperform | |
| GlaxoSmithKline | 3.55% | $108.80M | £82.75B | 38.66% | 77 Outperform | |
| BP p.l.c. | 3.27% | $100.43M | £79.00B | 23.28% | 71 Outperform | |
| Rio Tinto | 3.25% | $99.81M | £116.00B | 44.78% | 82 Outperform | |
| BAE Systems | 2.85% | $87.32M | £64.95B | 40.78% | 61 Neutral |